Business Wire

DroneBase Secures $55 Million and Launches Next Stage of Advanced Inspection Under New Brand Zeitview

7.2.2023 14:00:00 EET | Business Wire | Press release

Share

Further cementing its market leadership in advanced inspection software for energy and infrastructure, DroneBase has secured $55 million in investment and rebranded as Zeitview. Led by Valor Equity Partners, an operational growth investment firm backing technology and technology-enabled companies, the round was followed by existing investors Union Square Ventures, Upfront Ventures, Euclidean Capital, Energy Transition Ventures, and Hearst Ventures. The new funding will support the company’s AI-enabled software and global footprint in advanced inspection solutions. This announcement caps a year of rapid growth within the renewable sector, including the launch of the North American Solar Scan (NASS), the first standardized set of solar asset ratings to ensure better oversight of U.S. solar power plants. Last year, Zeitview inspected 43 GW of solar capacity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005174/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere. (Graphic: Business Wire)

As Zeitview, the company will continue building advanced inspection software that delivers fast, accurate insights, lowers costs for asset owners and improves performance and longevity. The name change comes with the company’s increasingly diverse data capture tools: alongside rotary wing drones, Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere.

“We appreciate how important time is to our customers: on the one hand, they need immediate and accurate analysis about the health of their assets; on the other, they are building energy and infrastructure resources to last for decades,” said Dan Burton, founder and chief executive officer at Zeitview. “We are confident that our AI-enabled software solutions can deliver that immediate answer and a long-term home for our customers, while we are increasingly agnostic about what tool we use to capture the most accurate data. We are grateful that Valor recognizes the power of our comprehensive services to support customers to build, protect, and maintain infrastructure across multiple asset classes and around the world. They understand transformational energy and infrastructure software and embrace businesses that use technology to solve operationally complex problems.”

Valor’s partnership enables Zeitview to continue transforming the aerial inspection industry with emerging technologies and exclusive AI software. Valor’s hands-on operational track record with complex software-led companies bolsters Zeitview’s commitment to increasing data capture capabilities through automation.

“Valor has been a long-term champion of data science and analytics to improve businesses,” said Vivek Pattipati, Partner at Valor Equity Partners. “With Zeitview’s continued expansion of services and commitment to delivering accurate, real-time insights through advanced inspection software, we are naturally mission-aligned. We look forward to supporting Zeitview as they launch this rebrand and enter the next phase of aerial imagery and data solutions.”

Zeitview means “time view” and better captures the nature of the company’s services and mission to accelerate the transition to renewable energy and sustainable infrastructure. In addition to providing real-time data, Zeitview offers long-term solutions to track changes across a period of time for an asset. Zeitview remains committed to building on the foundation of market leadership in drone services while engaging new tools for the evolving needs of the customer base. With last year’s launch of the NASS, the ability to serve as a one-stop shop for asset owners across multiple markets, and a continually expanding network of pilots around the globe, Zeitview is trailblazing the future of information gathering without limits.

For more information on how Zeitview makes aerial inspection data accessible across markets, please visit www.zeitview.com.

About Zeitview

For global customers in energy and infrastructure, Zeitview builds advanced inspection software that delivers fast, accurate insights, lowers costs, and improves asset performance and longevity. We are second to none at partnering with our customers to achieve flexible, long-term solutions across their multiple asset classes. Trusted by the largest enterprises in the world, Zeitview is active in over 70 countries. Learn more at www.zeitview.com.

About Valor Equity Partners

Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development. For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale. Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries. For more information on Valor Equity Partners, please visit www.valorep.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technica Communications
Cait Caviness
zeitview@technica.inc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye